This biological phenomenon of discordant EGFR mutations could partially account for the fact that some advanced NSCLC patients with wild-type EGFR respond to EGFR-TKI therapy and why some patients with well-known EGFR-TKI-sensitive mutations fail to respond to EGFR-TKI therapy. Here, EGFR is linked to non-small cell lung carcinoma.